Further studies must be conducted to clarify the optimal IHC assay, validate and standardize the definition of PD-L1 positivity, and explore the relationship among various expression levels of the PD-L1 protein, as well as the effect of such levels on the prognosis of lung cancer patients with PD-1/PD-L1-directed therapies. This evidence concerns the gene PDCD1 and lung cancer.